Revolution's Pancreatic Cancer Drug Doubles Survival and Enhances Quality of Life

• Daraxonrasib halted or reversed tumor progression in nearly 33% of patients versus 10% with chemotherapy, with tumors shrinking or disappearing in 31.6% versus 11.2% respectively
• While 86.3% of patients experienced rash, side effects were largely manageable with only 1.2% discontinuing treatment due to adverse events compared to 11.2% on chemotherapy
• The drug represents the first in a new class called RAS(ON) inhibitors and is already being tested in earlier-stage disease and combination therapies to extend survival benefits

Revolution Medicine's Pancreatic Cancer Drug Shows Breakthrough Results

Revolution Medicine's experimental pancreatic cancer pill, daraxonrasib, demonstrated remarkable efficacy in a 500-person clinical trial, reducing the overall risk of death by 60% compared to standard chemotherapy in patients who had failed one prior treatment round.

Key Trial Results:

• Median survival doubled to 13.2 months versus 6.7 months with chemotherapy
• Tumors shrank or disappeared in 31.6% of patients on daraxonrasib versus 11.2% on chemotherapy
• Cancer progression halted or reversed in nearly one-third of patients compared to 10% on chemotherapy
• In patients with G12 RAS mutation, tumors remained under control for 7.3 months versus 3.5 months with chemotherapy

Safety Profile:

• Rash occurred in 86.3% of patients but was largely manageable with antibiotics and topical steroids
• Only 1.2% discontinued treatment due to adverse events versus 11.2% on chemotherapy
• Severe side effects occurred in 43.6% of patients versus 57.5% in the chemotherapy group
• Most common side effects included mouth inflammation, nausea, diarrhea, and rash

Market Context:

Pancreatic cancer has the highest mortality rate among major cancers, with approximately 68,000 Americans diagnosed annually and 53,000 deaths expected this year. Only 3% of metastatic patients survive five years.

Clinical Significance:

Daraxonrasib is the first RAS(ON) inhibitor targeting RAS mutations present in up to 90% of pancreatic cancers. The drug improved quality of life sufficiently that patients resumed previously abandoned activities. Revolution Medicines is testing the drug in earlier-stage disease and combination therapies. The FDA has granted priority review for expedited approval consideration.